Obinutuzumab, a B-cell depleting therapy, is being explored for reducing lupus nephritis risks, such as flare.

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

Updated European Alliance of Associations for Rheumatology Guidelines on Lupus Nephritis The updated EULAR recommendations on the management of lupus nephritis (LN) were also presented. 6 Kidney ...

The study cohort comprised 41,095 patients with SLE, including 19,631 who received THA and 21,464 who received TKA. Overall, 30-day readmission rates were 6.1% for THA and 4.8% for TKA. Readmission ...

Fate Therapeutics, Inc. (NASDAQ:FATE) is among the best get rich quick stocks to buy now. Analysts at H.C. Wainwright have ...

Earlier use of combination therapies is purported to improve outcomes in many disease states, including lupus nephritis.

Objectives To compare the sensitivity of 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) classification criteria against 1997 ACR criteria for ...

A study found that combining the active ingredient extracted from the traditional Chinese medicine Astragalus membranaceus with the widely used Western drug methotrexate can effectively reduce chronic ...

Lupus can be debilitating and sometimes deadly for the 3 million people who have it. A treatment called CAR T appears to stop it in its tracks.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

Besides PsA, the company is targeting cutaneous lupus erythematosus (CLE) and a host of other primarily skin-related conditions. TYK2 is a different target from the Janus kinase (JAK) family of ...